Clinical research is for everyone

Inclusion is a major value for the EMN, particularly when it comes to clinical trials. The myeloma community is in fact highly heterogeneous and the EMN strongly believes that the same high-quality treatments should be offered to any patients, regardless of their gender, race, ethnicity, sexual orientation, disability, religion, age, cultural backgrounds, life experiences, thoughts, and ideas. We are extremely grateful for the fundamental role our patients play in the EMN clinical studies, and the contribution of each one of them is equally recognized and appreciated.

Carfilzomib in Combination with Bendamustine and dexamethasone in Refractory or Relapsed Multiple Myeloma
A multicenter, open label phase I/ii study of carfilzomib, pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma (mm) patients
A European Myeloma Network sequential phase I / phase II trial on RIC allogeneic transplantation: an optimized program for high risk relapsed patients (EMN-alloRIC)
A Randomized Phase III Study to Compare Bortezomib, Melphalan, Prednisone (VMP) With High Dose Melphalan Followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma
A phase 3, intergroup multicentre, randomized, controlled 3 arm parallel group study to determine the efficacy and safety of lenalidomide in combination with dexamethasone (rd) versus melphalan, prednisone and lenalidomide (mpr) versus cyclophosphamide, prednisone and lenalidomide (cpr) in newly diagnosed multiple myeloma elderly subjects